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Background/aim: We aimed to explore the roles of glycoprotein glycosylation in the pathogenesis of Kashin–Beck disease (KBD), and
evaluated the effectiveness of sodium hyaluronate treatment.
Materials and methods: Blood and saliva were collected from KBD patients before and after the injection of sodium hyaluronate. Normal
healthy subjects were included as controls. Saliva and serum lectin microarrays and saliva and serum microarray verifications were used
to screen and confirm the differences in lectin levels among the three groups.
Results: In saliva lectin microarray, bindings to Sophora japonica agglutinin (SJA), Griffonia (Bandeiraea) simplicifolia lectin I (GSL-I),
Euonymus europaeus lectin (EEL), Maackia amurensis lectin II (MAL-II), Sambucus nigra lectin (SNA), Hippeastrum hybrid lectin
(HHL), and Aleuria aurantia lectin (AAL) were higher in the untreated KBD patients than in the control group. Increased levels of
HHL, MAL-II, and GSL-I in the untreated KBD patients discriminated them in particular from the treated ones. Jacalin was lower in
the untreated KBD patients compared to the treated KBD and control groups. In serum lectin microarray, HHL and peanut agglutinin
(PNA) were increased in the untreated KBD group in comparison to the control one. AAL, Phaseolus vulgaris agglutinin (E+L) (PHAE+L), and Psophocarpus tetragonolobus lectin I (PTL-I) were lower in the untreated KBD patients compared to the treated KBD and
control groups. Hyaluronate treatment appeared to normalize SNA, AAL, and MAL-II levels in saliva, and HHL, PNA, AAL, PTL-I,
and PHA-E+L levels in serum. Saliva reversed microarray verification confirmed significant differences between the groups in SNA and
Jacalin, in particular for GSL-I levels, while serum reversed microarray verification indicated that HHL, PNA, and AAL levels returned
to normal levels after the hyaluronate treatment. Lectin blot confirmed significant differences in HHL, AAL, and Jacalin in saliva, and
HHL, PNA, PHA-E+L, and AAL in serum.
Conclusion: HHL in saliva and serum may be a valuable diagnostic biomarker of KBD, and it may be used as follow-up for the
hyaluronate treatment.
Key words: Kashin–Beck disease, carbohydrate chain, lectin microarray, serum, saliva

1. Introduction
Kashin–Beck disease (KBD) is an endemic
osteoarthritis, which is characterized by chondrocyte
necrosis and apoptosis, cartilage degeneration, and
extracellular matrix degradation. It is endemic in a
crescent-shaped area extending from southeastern
Siberia to northeastern and southwestern China. It
affects approximately 690,000 people and poses a high
risk to 10.584 million others residing in 366 counties
within 14 provinces or autonomous regions of China,
according to the 2010 Health Statistical Yearbook of
China [1].

The capacity for hyaluronate synthesis is decreased
in chondrocytes from patients with KBD. Exogenous
hyaluronate increases its synthesis in chondrocytes, which
provides the foundation for the theory that the KBD
patient should be treated with an intraarticular injection of
hyaluronate. Compared with the normal control group, IL1β and TNF-α levels were higher in the KBD group, while
their expression levels decreased after administration
of hyaluronate [2]. The levels of type II collagen and
aggrecan mRNAs were also lower in the KBD group. After
the administration of different doses of hyaluronate (100
and 500 mg/mL), their levels were significantly increased;
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500 mg/mL treatment led to a more significant effect [3].
Intraarticular injections of sodium hyaluronate effectively
reduced knee pain caused by KBD to a baseline value
measured by using the Western Ontario and McMaster
Universities Osteoarthritis (WOMAC) index [4].
Protein glycosylation plays a key role in a number of
biological processes, such as development, maintenance
of normal cellular functions, intercellular signaling,
protein folding, protein–protein interactions, cellular
differentiation, metabolism, and bacterial infections.
About half of human proteins are considered to be
modified with different glycosylation patterns [5]. Lectins
are carbohydrate-binding proteins which have been
used to discriminate carbohydrate structures, including
glycosaminoglycans, glycolipids, and glycoproteins in
a high-throughput manner based on slight structural
differences [6]. Oligosaccharides, which exist in human
saliva, include amino sugars, galactose, sialic acids (Sia),
xylose, fucose, and mannose. Proteins, which perform
many diverse functions, are modified by the glycan parts
of glycoproteins [7]. A lectin microarray is one of the main
ways to investigate variable glycosylation, as it can test
many different glycan bindings simultaneously [8].
The etiology of KBD remains unclear. Its pathogenesis
has not yet been fully defined. Currently, there are no
diagnostic or treatment follow-up indicators available for
KBD based on glycoprotein levels. In this study, we have
suggested that the glycosylation change in the salivary
and serous glycoproteins may involve the pathogenesis of
KBD, and may play a role in guiding treatment. Therefore,
we aimed at revealing whether such glycosylation
pattern differences are present in the saliva and serum
of KBD patients, and to investigate the role of knee joint
injection of sodium hyaluronate on the glycosylation in
the KBD patients. Lectin microarray was used to detect
the expression patterns of glycosylations. Reversed
microarrays and lectin blot were used to validate the
results of lectin microarray. Finally, this study evaluated
whether the identified potential lectins could be effective
as diagnostic biomarkers for KBD, and useful in the followup of sodium hyaluronate treatment of KBD.
2. Materials and methods
2.1. Whole saliva and venous blood samples collection
Patients with KBD (n = 35; 20 males, 15 females, 61 ±
5 years old) and normal control individuals (n = 38; 20
males, 18 females, 60 ± 6 years old) were recruited from
Linyou and Yongshou counties in Shaanxi Province, China.
All samples were excluded if the persons showed genetic
indications of bone or cartilage diseases, osteoarthritis,
or rheumatoid arthritis. Sodium hyaluronate (10 mg/mL,
2 mL) was injected into a knee joint of each patient with
KBD. Both venous blood and saliva were collected from

the KBD patients before and 2 weeks after the injection
(untreated KBD group, n = 35; treated KBD group, n =
35). Samples were also collected from the matched normal
group (n = 38). At least 2 h after the last intake of food, 3
mL of peripheral blood and 3 mL of unstimulated saliva
were collected; 0.9% saline was used to rinse participant’s
mouth before saliva was collected. Protease inhibitor
cocktail (1 µL/mL of saliva; Sigma, Darmstadt, Germany)
was added to the saliva immediately after collection. The
saliva was then centrifuged at 12,000 rpm, 30 min, 4 °C.
The supernatant was stored at –80 °C. Venous blood
samples were incubated at room temperature for 30 min.
The serum was collected by centrifugation at 3000 rpm for
5 min and then used immediately or stored at –80 °C.
Informed consent was obtained from each subject
involved in the investigation. All procedures performed in
the study involving human participants were in accordance
with the ethical standards of the Declaration of Helsinki
as revised in 1964. The study has the ethical approval of
the Ethics Management Committee of Xi’an Jiaotong
University (No: 2019-639).
2.2. Saliva and serum lectin microarrays
Twenty samples of saliva or serum from both the untreated
and the treated KBD groups were applied to the lectin
microarray. In addition, 20 samples from the control group
were also applied to the lectin microarray. Samples from
the untreated KBD, the treated KBD, and normal groups
were divided into subgroups by age (±5 years) separately.
The samples in each subgroup were pooled into one sample
separately. Pooled samples were then matched according
to sex. Saliva and serum lectin microarrays were produced
separately and incorporated 37 lectins (Sigma, Darmstadt,
Germany), which bind N- or O-linked glycans (shown
in Table 1). The arrangement of the lectin microarray is
shown in Figure 1. In brief, 37 lectins were dissolved in
the manufacturer’s recommended buffer and then spotted
on the homemade epoxysilane-coated slides with Stealth
microspotting pins (SMP-10B; TeleChem, Sunnyvale,
CA, USA) with a Capital smart microarrayer (CapitalBio,
Beijing, China). Every lectin was spotted in triplicate on
one slide. The protein labeled with Cy3 was diluted in 0.5
mL buffer containing 2% glycine, bovine serum albumin
(BSA), and 0.1% Tween-20. The mixture was then used in
the lectin microarrays. Finally, incubation was performed
in the chamber at 37 °C for 3 h [9].
2.3. Statistical analysis of saliva and serum lectin
microarrays
Three replicate slides of each sample were consistently
analyzed. We obtained primary fluorescence intensity value
of each lectin, then each value was globally normalized by
getting the ratio of each intensity value compared with
the sum of 37 lectin values. The mean of 3 replicate ratios
was the final fluorescence intensity value of each lectin.
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Table. The structures of the carbohydrate chains recognized especially by the lectins.
Lectin

Full name of the lectin

Specificity carbohydrate chain

ACA

Amaranthus caudatus

Galβ1-3GalNAcα-Ser/Thr (T antigen), sialyl-T(ST) tissue staining patterns
are markedly different than those obtained with either PNA or Jacalin

AAL

Aleuria aurantia lectin

Fucα1-6 GlcNAc(core fucose), Fucα1-3(Galβ1-4)GlcNAc

BPL

Bauhinia purpurea lectin

Galβ1-3GalNAc, Terminal GalNAc

BS-I

Bandeiraea simplicifolia

α-Gal, α-GalNAc, Galα-1,3Gal, Galα-1,6Glc

ConA

Canavalia ensiformis

High Mannose, Manα1-6(Manα1-3)Man, αMannose, αGlc

DBA

Dolichos biflorus agglutinin

αGalNAc, Tn antigen, GalNAcα1-3((Fucα1-2))Gal (blood group A antigen)

DSA

Datura stramonium

(GlcNAc) 2-4, polyLacNAc and LacNAc (NA3, NA4)

ECA

Erythrina cristagalli

Galβ-1,4GlcNAc (type II), Galβ1-3GlcNAc (type I)

EEL

Euonymus europaeus lectin

Galα1-3(Fucα1-2)Gal (blood group B antigen)

GNA

Galanthus nivalis

High-Mannose, Manα1-3Man

GSL-I

Griffonia (Bandeiraea) simplicifolia lectin I

αGalNAc, αGal, anti-A and B

GSL-II

Griffonia (Bandeiraea) simplicifolia lectin II
Hippeastrum
hybrid lectin

GlcNAc and agalactosylated tri/tetra antennary glycans

HHL

High-Mannose, Manα1-3Man, Manα1-6Man, Man5-GlcNAc2-Asn

Jacalin

Artocapus integrifolia

Galβ1-3GalNAcα-Ser/Thr(T), GalNAcα-Ser/Thr(Tn), GlcNAcβ1-3-GalNAcαSer/Thr(Core3), sialyl-T(ST). not bind to Core2, Core6, and sialyl-Tn (STn)

LCA

Lens culinaris agglutinin

α-D-Man, Fucα-1,6GlcNAc, α-D-Glc

LEL

Lycopersicon esculentum (tomato) lectin

(GlcNAc)n, high mannose-type N-glycans

LTL

Lotus tetragonolobus lectin

Fucα1-3Galβ1-4GlcNAc, Fucα1-anti-H blood group specificity

MAL-I

Maackia amurensis lectin I

Galβ-1,4GlcNAc

MAL-II

Maackia amurensis lectin II

Siaα2-3Galβ1-4Glc(NAc)/Glc, Siaα2-3Gal, Siaα2-3, Siaα2-3GalNAc

MPL

Maclura pomifera lectin

Galβ1-3GalNAc, GalNAc

NPA

Narcissus pseudonarcissus lectin

High-Mannose,Manα1-6Man

PHA-E+L Phaseolus vulgaris agglutinin (E+L)

Bisecting GlcNAc, bi-antennary N-glycans, tri- and tetra-antennary complextype N-glycan

PWM

Phytolacca americana

(GlcNAc)n and polyLacNAc

PSA

Pisum sativum agglutinin

Fucα-1,6GlcNAc,α-D-Man, α-D-Glc

PHA-E

Phaseolus vulgaris agglutinin (E)

Bisecting GlcNAc, biantennary complex-type N-glycan with outer Gal

PTL-I

Psophocarpus tetragonolobus lectin I

GalNAc, GalNAcα-1,3Gal, GalNAcα-1,3Galβ-1,3/4Glc

PTL-II

Psophocarpus tetragonolobus lectin II

Gal, blood group H, T-antigen

PNA

Peanut agglutinin

Galβ1-3GalNAcα-Ser/Thr(T)

RCA120

Ricinus communis agglutinin I

β-Gal, Galβ-1,4GlcNAc (type II), Galβ1-3GlcNAc (type I)

SJA

Sophora japonica agglutinin

Terminal in GalNAc and Gal, anti-A and anti-B human blood group

STL

Solanum tuberosum (potato) lectin

trimers and tetramers of GlcNAc, core (GlcNAc) of N-glycan, oligosaccharide
containing GlcNAc and MurNAc

SBA

Soybean agglutinin

α- or β-linked terminal GalNAc, (GalNAc)n, GalNAcα1-3Gal, blood-group A

SNA

Sambucus nigra lectin

Sia2-6Gal/GalNAc

UEA-I

Ulex europaeus agglutinin I

Fucα1-2Galβ1-4Glc(NAc)

VVA

Vicia villosa lectin

terminal GalNAc, GalNAcα-Ser/Thr(Tn), GalNAcα1-3Gal

WFA

Wisteria floribunda lectin

terminating in GalNAcα/β1-3/6Gal

WGA

Triticum vulgaris

Multivalent Sia and (GlcNAc)n
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Figure 1. Layout of 37 lectins, the negative control (bovine serum albumin, BSA), and a positive marker contained in saliva or serum
lectin microarray.

Subsequently, we separately compared the means of paired
groups (untreated KBD/treated KBD, untreated KBD/
normal, and treated KBD/normal). Fold changes ≥1.5 or
≤0.67 between the pairs indicated up- or down-regulation
of each lectin, respectively.
2.4. Saliva and serum reversed microarrays verification
A reversed microarray analysis was used to verify the lectin
microarray results. Salivary and serous protein samples
from 15 untreated KBD patients, 15 KBD patients treated
with sodium hyaluronate, and 18 normal individuals were
spotted in triplicate on the microarray. The Cy3-labeled
lectins were applied to detect the specific glycan structures
in the salivary and serous protein samples, which were
immobilized on the slides. Lectins GSL-I, SNA, and Jacalin
were selected for saliva microarrays, and HHL, AAL, and
PNA for serum microarrays. The slides were scanned
using a Genepix 4000B confocal scanner, and the acquired
images were analyzed at 532 nm to detect Cy3.
2.5. Statistical analysis of saliva and serum microarrays
verification
Significant differences between the untreated KBD, the
treated KBD, and the normal groups were calculated using

one-way ANOVA with SPSS Statistics 19 (IBM, Armonk,
NY, USA). Differences were considered statistically
significant for values of P < 0.05.
2.6. Lectin blot analysis
In order to further confirm the different abundance of
significant glycans, the SDS-PAGE and lectin blotting
analysis was performed with 3 lectins (HHL, AAL, and
Jacalin)in pooled saliva group samples and 4 lectins (HHL,
PNA, PHA-E+L, and AAL) in both pooled saliva group
samples and pooled serum group samples of the normal
control, the untreated KBD, and the treated KBD groups
separately. In brief, the samples were run on a 10% SDSPAGE polyacrylamide resolving gel and a 3% stacking
gel. Afterwards, the proteins in the gels were transferred
to a PVDF membrane (MilliporeSigma, Burlington, MA,
USA) with a wet transfer unit (Hoefer Scientific, Holliston,
MA, USA) at 100 V for 1.5 h. The membrane was washed
twice with TTBS (10 mmol/L Tris-HCl, 150 mmol/L NaCl,
0.05% Tween-20, pH 7.5) and blocked with Carbo-Free
Blocking Solution (Vector, Burlingame, CA, USA) for
1 h at room temperature. The membrane was incubated
with Cy5-labeled (GE Healthcare, Buckinghamshire,
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UK) lectins (2 mg/) at 4 °C overnight in the dark. Finally,
the membrane was scanned using a phosphorimager
(Molecular Dynamics Inc., Sunnyvale, CA, USA) [9].
3. Results
3.1. Differential lectins in saliva and serum lectin
microarrays
Saliva lectin microarray showed significant differences
in the fluorescence intensities of 8 lectins between the
untreated KBD, the treated KBD, and the normal groups
(Figure 2). Stronger signals for SJA, GSL-I, EEL, MAL-II,
SNA, HHL, and AAL were observed in the saliva from
the untreated KBD patients than from the treated patients
with KBD and the control group. Meanwhile, Jacalin signal
was lower in the saliva from the untreated KBD patients
and the treated KBD group in comparison with the control
group. After hyaluronate treatment, the levels of SNA,
AAL, and MAL-II appeared to return to approximately
normal levels.
In the serum lectin microarray (Figure 3), significant
differences in the fluorescence intensities of 5 lectins were
observed between the untreated KBD, the treated KBD,
and the control groups. Strong signals of HHL and PNA
were typical for the samples of the untreated KBD group
in comparison to the normal ones. Meanwhile, decreased
AAL, PHA-E+L, and PTL-I signals were observed in

the serum samples of the KBD patients. Hyaluronate
treatment appeared to normalize the levels of HHL, PNA,
AAL, PHA-E+L, and PTL-I.
3.2. Differential lectins in saliva and serum microarrays
verification
Salivary protein microarray showed significantly stronger
GSL-I signal in the untreated KBD patients (Figure 4).
Significantly elevated SNA signal levels in the untreated
patients were normalized by the hyaluronate treatment,
although the level still remained higher than in the control
group (Figure 4). Saliva from the untreated patients
had significantly lower levels of Jacalin than the healthy
controls (Figure 4).
Data from serum microarray verification showed that
significantly increased levels of HHL and PNA signals in
the untreated KBD group declined to the control level in
the treated group (Figure 5). A significantly decreased
level of AAL signal in the untreated KBD group increased
to the control level in the treated group (Figure 5).
3.3. Lectin blot analysis
The different abundance of glycans among normal control
(healthy), the untreated KBD (UK), and the treated KBD
(TK) groups were confirmed by the lectin blotting analysis
with 3 lectins (HHL, AAL, and Jacalin) in saliva samples
and 4 lectins in serum samples (HHL, PNA, PHA-E+L,
and AAL). The results of the lectin blotting analysis

Figure 2. Salivary glycoprotein glycosylation patterns determined with Cy3-labeled lectins spotted onto a lectin microarray. UK:
untreated KBD patients; TK: treated KBD patients; Healthy: normal controls. a. Profiles of Cy3-labeled salivary proteins from the UK,
the TK, and the healthy individuals bound to the lectin microarrays. The lectin microarrays revealed significant lectins marked with
white rectangles. b. Significant differences in the lectin levels between the three groups. The bars show mean ± SD of three biological
replicates from each group.
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Figure 3. a. Serous glycoprotein expression levels were determined with Cy3-labeled lectins using a lectin microarray. UK: untreated
patients with KBD; TK: treated patients with KBD; Healthy: normal controls. The lectin microarrays revealed significant lectins marked
with white rectangles. b. Significant differences in the lectin levels between the three groups. The bars show mean ± SD of three biological
replicates from each group.

showed apparent bands belonging to different molecular
weights ranging from 15 to 250 kDa. The apparent bands
were marked as L1–L10 (Figures 6 and 7).
Among the selected lectins, HHL showed stronger
binding to 2 bands between 70 and 100 kDa (L1, L2),
2 bands between 25 and 50 kDa (L4, L5), and 1 band
between 15 and 20 kDa (L6) in the saliva of the UK group
than in the TK group, and also showed stronger binding in
the TK group than in the healthy group.
AAL showed stronger binding to one band between
15 and 20 kDa (L6) in the saliva of the UK group than to
the TK and the healthy groups. On the contrary, Jacalin
exhibited weaker binding to 2 bands between 100 and

250 kDa (L1, L2) and 1 band between 25 and 50 kDa (L6)
in the saliva of the UK group than in the TK group, and
also showed weaker binding in the TK group than in the
healthy group (Figure 6).
HHL showed stronger binding to one band 70 kDa
(L4) in the serum of the UK group than in the TK and
healthy groups. PNA showed stronger binding to one band
70 kDa (L1) in the serum of the UK group than in the TK
and healthy groups. On the contrary, PHA-E+L exhibited
weaker binding to one band 50–70 kDa (L5) in the serum
of the UK group than in the TK and healthy groups. AAL
also exhibited weaker binding to one band 70–100 kDa
(L2) and one band 50–70 kDa (L3) in the serum of the
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Figure 4. Verification of the differences in the saliva levels of the three lectins GSL-1, SNA, and Jacalin. UK: untreated patients with
KBD; TK: treated patients with KBD; Healthy: normal controls. a. Scanned pictures of Cy3-labeled lectins bound to the salivary protein
microarrays. b. Box plot analysis of the salivary microarray data obtained from the three groups. Error bars show 95% confidence
intervals for mean values. The P-values indicate the statistical significance of differences between the groups. c. Scatter plot analysis of
the salivary protein microarray data obtained from the three groups. Lines show mean ± SEM.

UK group than in the TK and healthy groups (Figure 7).
The results were coincident with the results from the lectin
microarrays.
4. Discussion
Glycosylation is one of the most common posttranslational
modifications of secreted proteins and plays a significant
role in cell–cell interactions, cell adhesion, malignant
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transformation, and metastasis [10]. It also has an
important role in the molecular recognition events of
the body. The glycosylation patterns of glycoproteins
provide clues about cell metabolism and the expression
and function of oligosaccharides. Glycoproteins can exist
in many glycosylated variants, and the distribution of
different classes of oligosaccharide structures is most often
specific for each glycosylation site [11].

WANG et al. / Turk J Med Sci

Figure 5. Verification of the differences in the sera levels of the three lectins HHL, PNA, and AAL. UK: untreated patients with
KBD; TK: treated patients with KBD; Healthy: normal controls. a. Scanned pictures of Cy3-labeled lectins bound to the serous protein
microarrays. b. Box plot analysis of the serous microarray data obtained from the three groups. Error bars show 95% confidence intervals
for mean values. The P-values indicate the statistical significance of differences between groups. c. Scatter plot analysis of the serous
protein microarray data obtained from the three groups. Lines show mean ± SEM.

Figure 6. Lectin blot analysis of the differential expressions of the glycopatterns in the saliva from three groups: Healthy: normal
control; UK: untreated KBD; TK: treated KBD. The three groups of saliva pooled samples using 3 lectins (HHL, AAL, and Jacalin). The
apparent bands belong to different molecular weights ranging from 15 to 250 kDa, which are marked as L1–L8, respectively.

Although serum is frequently used as a sample to
analyze various biomarkers, saliva is also a good indicator
of the plasma levels of various substances. Although both
saliva and serum are samples from systemic sources, the
components derived from tissues such as cartilage can
accumulate in them. The extracellular matrices of tissues
such as the cornea, hyaline cartilage, and nucleus pulposus
of the intervertebral disks are rich sources of glycoproteins
and proteoglycans (PGs) [12]. More importantly, shifts in
the glycosylation patterns have been identified in diseases,

such as in IgG of the serum of rheumatoid arthritis
patients [13], which was later found to be responsible for
the activation of the complement system [14]. Lectins can
be valuable tools in the diagnosis of diseases, and even in
discrimination of their stages [15], although the actual
protein with altered glycosylation and/or its function
would not be known.
In this study, the goal was to identify changes in
glycosylation patterns in KBD by using a group of lectins.
Hyaluronate treatment has been reported to alleviate the
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Figure 7. Lectin blot analysis of the differential expressions of
the glycopatterns in the sera from three groups: Healthy: normal
control; UK: untreated KBD; TK: treated KBD. The three groups
of saliva pooled samples using 4 lectins (HHL, PNA, PHA-E+L,
and AAL). The apparent bands belong to different molecular
weights ranging from 15 to 250 kDa, which are marked as L1–
L10, respectively.

symptoms of KBD patients [4]. Therefore, we also screened
whether the treatment would reveal lectin levels, which
are altered in KBD but normalized by hyaluronate therapy,
since they could be useful in evaluating the efficacy of
the treatment. As a result, the first screening experiments
identified several lectins which had differential expression
levels in the KBD saliva and serum in comparison to the
normal samples. Three of those lectins (GSL-I, SNA, and
Jacalin) were selected for the verification microarray of
saliva samples, and three were selected for serum samples
(HHL, PNA, and AAL). The carbohydrate chain Galα13-Gal is recognized by PNA, high mannose is recognized
by HHL, and GlcNAc is recognized by AAL, Jacalin, and
PHA-E+L.
The glycosylation pattern changes can have marked
effects in the functions of proteins. Previously, the levels
of the Galα1,3-Gal antigen reduced in HT-transgenic
porcine cartilage conferred resistance to delayed rejection
[16]. Expression levels of high mannose-type N-glycans
were significantly increased at the later stages of mouse
chondroprogenitor cell differentiation. On the other hand,
the levels of some high mannose-type N-glycans were
recently shown to be significantly decreased in both human
OA cartilage and degraded mouse cartilage [17,18].
In developing rat embryos, the presence of numerous
lectin binding affinities has been associated with a general
reduction of oligosaccharide structures during development
[19]. Primary OA chondrocytes are characterized by
significantly higher levels of high mannose-type N-glycans
and sialic acid-capped N-glycans compared to chondrocyte
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cell lines. In immortalized chondrocyte cell lines, the
patterns of O- and N-linked oligosaccharides appear to be
shifted toward reduced levels of high mannose-type and
sialic acid-capped N-glycans, as well as increased levels of
fucosylated O-glycosylation products [20]. An alteration
in high mannose-type N-glycans has been attributed to
the expression of the Mgat1 gene, which regulates the
expression of the key proteases matrix metalloprotease-13
and aggrecanase-2 during the cartilage degradation
process [18]. Additionally, the levels of high mannosetype N-glycans in primary human chondrocytes decrease
in response to inflammatory cytokines IL-1β and TNF-α
[21]. The GlcNAc-accelerated production of hyaluronate is
associated with the induction of hyaluronate synthase-2, a
key enzyme involved in hyaluronate synthesis [22].
Intraarticular hyaluronate injection has been proposed
to have many therapeutic mechanisms of action in the OA
knee, including antiinflammatory effects, joint lubrication,
shock absorption, chondroprotection, proteoglycan
synthesis, and cartilage matrix alteration. At present, there
are no good indicators for how to observe the biological
effects of the treatment. Lectin analysis may be a potential
assay for the follow-up of hyaluronate treatment, not only
for KBD, but also for other forms of arthritis. In both the
saliva and serum samples, HHL signal was stronger in
the patients with KBD than in the normal controls and
normalized after hyaluronate treatment. HHL binding
was the best marker to differentiate the KBD patients from
the controls. It also differentiated between the untreated
and the hyaluronate-treated groups and, thus, might be a
valid biomarker to evaluate the efficacy of the treatment.
We plan to analyze the lectin levels in chondrocytes and
to confirm diagnostic biomarkers of KBD in the next
step. The method used to reveal the differences in the
glycopatterns of human salivary and serous glycoproteins
may provide pivotal information to help researchers
understand other bone joint diseases. The selected lectins
can only indicate changes in overall glycosylation patterns,
but do not identify specific proteins involved. Therefore,
the effects of these changes on protein functions cannot
be defined by these analyses. However, it does not reduce
the value which this type of assay can have in the diagnosis
of KBD.
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